Physicians are cautioned that the two obstacles to reforming post-marketing clinical trials are the FDA's reluctance to revisit past approvals and its inability to enforce pharmaceutical companies' commitment to conduct Phase IV trials.
Dr Noah Boton joins Ethics Talk to discuss his article, coauthored with Dr Jeffrey Larnard: “When Should Patients at the End of Life Get Antimicrobials?”
Dr Jeannie P. Cimiotti joins Ethics Talk to discuss her article, coauthored with Drs Kimberly Adams Tufts, Lucia D. Wocial, and Elizabeth Peter: “How Should Focus Be Shifted From Individual Preference to Collective Wisdom for Patients at the End of Life With Antimicrobial-Resistant Infections?”
Physicians need to manage expectations and clearly explain the prognosis of ICU patients to their families, particularly when the outcome is a negative one.
A physicians urges practitioners to use cost-effective alternatives to dispensing samples to patients who cannot afford to pay for their prescriptions.
A physician explains that the sale of nonprescription cosmeceuticals from a dermatology office should be done in a manner that is educational but non-threatening to patients.
A physician and a lawyer argue against a dermatology clinic switching from a small, reliable pathology lab to a large-scale pathology lab in order to receive volume discounts and increase profit.
Physicians should be aware of the level of emotional distress and suffering that a patient is experiencing as a result of his or her illness and incorporate that into the patient's treatment plan.